Hydralazine/isosorbide dinitrate

Drug Profile

Hydralazine/isosorbide dinitrate

Alternative Names: AR-06; BiDil; BiDil XR; Heart failure therapy - NitroMed; Hydralazine hydrochloride/isosorbide dinitrate; Isosorbide dinitrate/hydralazine

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator NitroMed
  • Developer Arbor Pharmaceuticals; NitroMed
  • Class Heart failure therapies; Organic nitrates; Peripheral vasodilators; Phthalazines; Small molecules
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure

Most Recent Events

  • 30 Apr 2016 Arbor Pharmaceuticals completes a phase I/II trial in Heart failure in USA (NCT02522208)
  • 01 Sep 2015 Phase-I/II clinical trials in Heart failure in USA (PO, controlled-release)
  • 05 Aug 2015 Arbor Pharmaceuticals plans a phase I/II trial for Heart failure in USA (PO, Controlled release) (NCT02522208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top